Post-COVID-19 Pneumo-hematocele (PHC)

October 1, 2021 updated by: Karla Verónica Chavez-Tostado, Hospital General Ajusco Medio

Post COVID-19 Pneumo-hematocele: Clinical Presentation and Treatment Pathway

Introduction. As the COVID-19 pandemic has continued, an increasing number of long-term complications are emerging. Recently, the appearance of characteristic pulmonary lesions has been noted, being described as post COVID-19 pneumatocele. The aim of this study is to describe the clinical, histopathologic and imaging features of post COVID-19 pneumo-hematoceles (PHC) and secondarily to suggest a treatment algorithm in these patients.

Methods. A retrospective study was performed in patients admitted with diagnosis of SARS-CoV2 infection from March 2020 to September 2021 who presented PHC on imaging studies. Clinical and demographic variables were recorded and CT scans were analyzed. A logistic regression analysis was performed to determine the risk for rupture according to PHC characteristics.

It appears that PHC occurs secondary to encapsulation of blood accumulation, the result of micro capillary bleeding, with partial reabsorption of blood and subsequent air filling. The recommendation is to operate on patients with PHC of 5cm and those with persistent lesions of 3cm.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

37

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Mexico
      • Mexico City, Mexico, 14500
        • Karla Verónica Chávez Tostado

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with a positive chain reaction for SARS CoV-2 who had PHC on imaging studies in two hospitals of Mexico City

Description

Inclusion Criteria:

  • Adults with a positive protein chain reaction for SARS-CoV2,
  • PHC on imaging studies.

Exclusion Criteria:

  • loss of follow up
  • age out of range.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Pneumohematocele
Patients with SARS CoV-2 diagnosis and PHC on imaging studies
Procedure: Pulmonary resection
Resection of pneumohematocele

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PHC diagnosis
Time Frame: From date of diagnosis until 4 weeks after diagnosis
Pneumohematoceles on imaging studies
From date of diagnosis until 4 weeks after diagnosis

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital General Ajusco Medio

Collaborators

Instituto Nacional de Enfermedades Respiratorias

Investigators

  • Principal Investigator: Karla V Chavez Tostado, MD, Head of surgery department

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2020

Primary Completion (Actual)

March 1, 2020

Study Completion (Actual)

September 20, 2021

Study Registration Dates

First Submitted

September 28, 2021

First Submitted That Met QC Criteria

October 1, 2021

First Posted (Actual)

October 5, 2021

Study Record Updates

Last Update Posted (Actual)

October 5, 2021

Last Update Submitted That Met QC Criteria

October 1, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HGAM02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe